2,5-bis(4-nitrophenyl)-1H-imidazole | 783363-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,5-bis(4-nitrophenyl)-1H-imidazole
• CAS: 783363-93-9
• 化学式: C₁₅H₁₀N₄O₄
• 分子量: 310.269
• InChiKey: KHJRSWZDPMDFJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,5-bis(4-nitrophenyl)-1H-imidazole 在 盐酸 、 氢气 、 palladium(II) hydroxide 、 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 生成 (2S)-1-(2-phenylacetyl)-N-[4-[2-[4-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]phenyl]-1H-imidazol-4-yl]phenyl]pyrrolidine-2-carboxamide
  参考文献：
  名称：

  HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies

  摘要：

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.086
• 作为产物：
  描述：

  2,4-二苯基咪唑 在 硝酸 作用下， 生成 2,5-bis(4-nitrophenyl)-1H-imidazole
  参考文献：
  名称：

  HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies

  摘要：

  In a recent disclosure,(1) we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting < 10 nM EC50 in a genotype 1b replicon assay. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.086

文献信息

• [EN] IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS<br/>[FR] DERIVES D'IMIDAZOLE DESTINES AU TRAITEMENT DE TROUBLES ALLERGIQUES ET HYPERPROLIFERATIFS
  申请人：AVANIR PHARMACEUTICALS

  公开号：WO2004091610A1

  公开（公告）日：2004-10-28

  The preferred embodiments are directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The preferred embodiments also relate to imidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. The preferred embodiments further relate to small molecules which suppress cytokines and leukocytes.

  首选实施例涉及对过敏原的IgE反应的小分子抑制剂，这些抑制剂在过敏和/或哮喘或任何IgE具有致病性的疾病的治疗中是有用的。首选实施例还涉及咪唑分子，这些分子是细胞增殖抑制剂，因此可用作抗癌剂。首选实施例还涉及抑制细胞因子和白细胞的小分子。
• Imidazole derivatives for treatment of allergic and hyperproliferative disorders
  申请人：——

  公开号：US20040229927A1

  公开（公告）日：2004-11-18

  The preferred embodiments are directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The preferred embodiments also relate to imidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. The preferred embodiments further relate to small molecules which suppress cytokines and leukocytes.

  首选实施例是针对IgE对过敏原的反应的小分子抑制剂，这些抑制剂在过敏和/或哮喘或任何IgE为致病因素的疾病的治疗中有用。首选实施例还涉及咪唑分子，这些分子是细胞增殖抑制剂，因此可用作抗癌剂。首选实施例还涉及抑制细胞因子和白细胞的小分子。
• EP1613310A1
  申请人：——

  公开号：EP1613310A1

  公开（公告）日：2006-01-11